Search research articles
Contact Us
Filters
Showing results (801-810 of 829) with videos related to
Page
of 83
Sort By:
Arthritis Research & Therapy
|
July 6, 2016
Erratum to: The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study
Ruben Burgos-Vargas, James Cheng-Chung Wei, Mahboob U Rahman, et al.
American Journal of Ophthalmology
|
January 27, 2026
Risk of Glaucoma in Patients With Idiopathic Non-Infectious Uveitis: A Multi-Institutional Real-World Retrospective Cohort Study
De-Yi Liu, Hou-Ting Kuo, Alan Y Hsu, et al.
Annals of the Rheumatic Diseases
|
July 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, et al.
Ophthalmology
|
November 13, 2024
Risk of Uveitis among E-Cigarette Users: A Multi-institutional TriNetX Study
Alan Y Hsu, Yu-Hsun Wang, Ning-Yi Hsia, et al.
Japanese Journal of Clinical Oncology
|
October 8, 2022
The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
Cho-Han Chiang, Cho-Hung Chiang, Kevin Sheng-Kai Ma, et al.
Lancet (London, England)
|
October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Annals of the Rheumatic Diseases
|
June 28, 2018
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, et al.
Arthritis Care & Research
|
May 9, 2017
Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study
Maxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
International Journal of Rheumatic Diseases
|
March 1, 2019
2018 APLAR axial spondyloarthritis treatment recommendations
Lai Shan Tam, James Cheng-Chung Wei, Amita Aggarwal, et al.
AIDS Research and Therapy
|
July 11, 2025
Risk of uveitis in patients with human immunodeficiency virus: a cohort study through TriNetX database
Bing-Qi Wu, Hou-Ting Kuo, Alan Y Hsu, et al.
Page
of 83
Search research articles
Search
Showing results (801-810 of 829) with videos related to
Sort By:
Page
of 83
Arthritis Research & Therapy
|
July 6, 2016
Erratum to: The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study
Ruben Burgos-Vargas, James Cheng-Chung Wei, Mahboob U Rahman, et al.
American Journal of Ophthalmology
|
January 27, 2026
Risk of Glaucoma in Patients With Idiopathic Non-Infectious Uveitis: A Multi-Institutional Real-World Retrospective Cohort Study
De-Yi Liu, Hou-Ting Kuo, Alan Y Hsu, et al.
Annals of the Rheumatic Diseases
|
July 28, 2019
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, et al.
Ophthalmology
|
November 13, 2024
Risk of Uveitis among E-Cigarette Users: A Multi-institutional TriNetX Study
Alan Y Hsu, Yu-Hsun Wang, Ning-Yi Hsia, et al.
Japanese Journal of Clinical Oncology
|
October 8, 2022
The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
Cho-Han Chiang, Cho-Hung Chiang, Kevin Sheng-Kai Ma, et al.
Lancet (London, England)
|
October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Annals of the Rheumatic Diseases
|
June 28, 2018
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten, Mikkel Østergaard, James Cheng-Chung Wei, et al.
Arthritis Care & Research
|
May 9, 2017
Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study
Maxime Dougados, Désirée van der Heijde, Joachim Sieper, et al.
International Journal of Rheumatic Diseases
|
March 1, 2019
2018 APLAR axial spondyloarthritis treatment recommendations
Lai Shan Tam, James Cheng-Chung Wei, Amita Aggarwal, et al.
AIDS Research and Therapy
|
July 11, 2025
Risk of uveitis in patients with human immunodeficiency virus: a cohort study through TriNetX database
Bing-Qi Wu, Hou-Ting Kuo, Alan Y Hsu, et al.
Page
of 83